Al Hammadi Holding announces its Interim Financial results for the Period Ending on 2026-06-30 ( Six Months )

lement ListCurrent QuarterSimilar quarter for previous year%ChangePrevious Quarter% Change
Sales/Revenue321.75298.247.882319.090.833
Gross Profit (Loss)79.9392.99-14.044101.09-20.931
Operational Profit (Loss)69.5463.898.84352.5532.331
Net Profit (Loss) Attributable to Shareholders of the Issuer71.8961.9616.02656.2427.827
Total Comprehensive Income Attributable to Shareholders of the Issuer72.6962.9415.4952.7637.774
All figures are in (Millions) Saudi Arabia, Riyals
Element ListCurrent PeriodSimilar period for previous year%Change
Sales/Revenue640.84600.126.785
Gross Profit (Loss)181.02189.5-4.474
Operational Profit (Loss)122.09140.62-13.177
Net Profit (Loss) Attributable to Shareholders of the Issuer128.13135.89-5.71
Total Comprehensive Income Attributable to Shareholders of the Issuer125.45138.19-9.219
Total Shareholders Equity (after Deducting Minority Equity)2,066.621,987.443.984
Profit (Loss) per Share0.80.85
All figures are in (Millions) Saudi Arabia, Riyals
Element ListAmountPercentage of the capital (%)
Profit (Losses) Resulting From The Change In Investment Propertie’s Fair Value
All figures are in (Millions) Saudi Arabia, Riyals
Element ListExplanation
The reason of the increase (decrease) in the sales/ revenues during the current quarter compared to the same quarter of the last year isThe company’s revenue increased by 7.9% during the second quarter of the current year to reach 321.75 million Saudi Riyals , compared to 298.24 million Saudi Riyals for the same quarter of the previous year. This growth was primarily driven by the performance of the company’s main business segments; the Pharmaceutical Products Segment posted a 24.4% growth to reach 72.08 million Saudi Riyals (compared to 57.92 million Saudi Riyals) due to higher retail sales at the subsidiary, while the Medical Services Segment enhanced total revenues with a 3.9% increase, generating 249.67 million Saudi Riyals compared to 240.32 million Saudi Riyals in the corresponding quarter of the previous year.
The reason of the increase (decrease) in the net profit during the current quarter compared to the same quarter of the last year isThe company’s net profit increased during the second quarter of 2026 by 16.0% year-on-year to reach 71.89 million Saudi Riyals, compared to 61.96 million Saudi Riyals for the same quarter of the previous year.This increase is mainly attributed to the following reasons:1) Revenues: Company revenues during the current quarter rose by 7.9% to reach 321.75 million Saudi Riyals, compared to 298.24 million Saudi Riyals for the corresponding quarter of the previous year.2) Expected Credit Losses Provision: A reversal of expected credit losses (ECL) provision amounting to 9.17 million Saudi Riyals was recorded in the current quarter, compared to a provision charge of 10.91 million Saudi Riyals in the same quarter of the previous year, driven by an improvement in collection pace from key clients.3) Gain on Disposal of Property and Equipment: A gain of 6.99 million Saudi Riyals was recognized on the disposal of property and equipment, resulting from the compulsory expropriation of a parcel of land owned by the company in northeast Riyadh (Al-Munsiyah district), as previously announced on the Tadawul website on June 28, 2026.4) Share of Profit from Associates: Reached 14.69 million Saudi Riyals for the current quarter, representing an increase of 108.13% compared to 7.06 million Saudi Riyals for the same quarter of the previous year.
The reason of the increase (decrease) in the sales/ revenues during the current quarter compared to the previous one isThe company’s revenues stabilized in the second quarter of 2026 at 321.75 million Saudi Riyals, remaining at a close level to the first quarter of the same year (319.09 million Saudi Riyals), representing a slight increase of 0.8%.This slight increase was primarily driven by a 1.1% growth in the Medical Services Segment revenues, which reached 249.67 million Saudi Riyals in the current quarter compared to 246.94 million Saudi Riyals in the previous quarter.
The reason of the increase (decrease) in the net profit (loss) during the current quarter compared to the previous one isThe company continued to strengthen its financial performance during the second quarter of 2026, with net profit growing by 27.8% compared to the first quarter of the current year, reaching 71.89 million Saudi Riyals up from 56.24 million Saudi Riyals.This quarter-on-quarter growth is primarily driven by the following factors:1) Expected Credit Loss (ECL) Provision: A reversal of expected credit losses provision amounting to 9.17 million Saudi Riyals was recorded in the current quarter, compared to a provision charge of 17.31 million Saudi Riyals in the previous quarter, as a result of an improved collection pace from key clients during Q2 compared to Q1.2) General, Administrative, and Marketing Expenses: Total general, administrative, and marketing expenses for the current quarter decreased by 6.44 million Saudi Riyals to reach 30.44 million Saudi Riyals, compared to 36.88 million Saudi Riyals for the previous quarter. This was mainly due to a decline in promotional expenses and advertising costs during the second quarter compared to the first quarter.3) Gain on Disposal of Property and Equipment: A gain of 6.99 million Saudi Riyals was recognized on the disposal of property and equipment, resulting from the compulsory expropriation of a parcel of land owned by the company in northeast Riyadh (Al-Munsiyah district), as previously announced on the Tadawul website on June 28, 2026.
The reason of the increase (decrease) in the sales/ revenues during the current period compared to the same period of the last year isThe company’s total revenue for the first half of 2026 recorded a 6.8% year-on-year growth, reaching 640.84 million Saudi Riyals, compared to 600.12 million Saudi Riyals for the same period in 2025.This increase was the result of growth across the company’s main business segments, detailed as follows:1) Pharmaceutical Products Segment: Revenue grew by 21.0% to reach 144.23 million Saudi Riyals for the current period (compared to 119.24 million Saudi Riyals for the same period last year), driven by higher retail sales at the subsidiary level.2) Medical Services Segment: Continued to support total revenue by achieving a 3.3% growth, with its revenue reaching 496.61 million Saudi Riyals, compared to 480.88 million Saudi Riyals for the same period of the previous year.
The reason of the increase (decrease) in the net profit during the current period compared to the same period of the last year isThe company’s net profit decreased during the first half of 2026 by 5.7% year-on-year to reach 128.13 million Saudi Riyals, compared to 135.89 million Saudi Riyals for the same period in 2025.This decrease is mainly attributed to the following factors:1) Gross Profit Margin: The gross profit margin percentage declined during the current period to reach 28.2%, compared to 31.6% for the same period last year, driven by an increase in some operating cost items.2) General, Administrative, and Marketing Expenses: Total general, administrative, and marketing expenses for the current period increased by 16.62 million Saudi Riyals to reach 67.31 million Saudi Riyals (compared to 50.69 million Saudi Riyals for the same period last year). This was primarily due to the marketing campaign and promotional costs associated with the launch of Al Hammadi Hospitals Group’s new brand identity.3) Other Income: A decrease in other income by 2.86 million Saudi Riyals compared to the same period of the previous year.4) Finance Income and Finance Costs: Finance income for the current period declined by 3.09 million Saudi Riyals, while finance costs increased by 2.83 million Saudi Riyals to reach 15.20 million Saudi Riyals (compared to 12.37 million Saudi Riyals for the same period last year). This was a result of the accelerated construction works for the Al Olaya Al Hammadi Hospital branch and the management of liquidity and borrowings to ensure the smooth continuity of both operational and construction activities.
Statement of the type of external auditor’s reportUnmodified conclusion
Comment mentioned in the external auditor’s report, mentioned in any of the following paragraphs (other matter, conservation, notice, disclaimer of opinion, or adverse opinion)None
Reclassification of Comparison ItemsNone
Additional InformationNone

Pharmaceutical Services

Pharmaceutical Services Company, a subsidiary of Al Hammadi Holding, is a leading provider of essential medications, vaccinations, and drug distribution services. As a key component of Al Hammadi’s comprehensive health care offering, the Pharmaceutical Services Company plays a vital role in ensuring that patients have access to the necessary treatments to support their health and well-being.

Continuing Medical Education (CME)

The Continuing Medical Education (CME) was established in 1985 to meet the education and training needs of all hospital staff, whether medical personnel, doctors or non-medical staff nurses, assistants or technicians.

Training Institutes Women

The Support Services Institutes for Training opened branches for (women) in Riyadh, Kingdom of Saudi Arabia in 2020, after the complete acquisition (100%) of Najd Training Institutes, which was established in 1986 AD. Thus, the Support Services Institutes have become one of the leading and specialized institutes in the field of training and education. and development.

Training Institutes Men

The Support Services Institutes for Training opened branches for(Men) in Riyadh, Kingdom of Saudi Arabia in 2020, after the complete acquisition (100%) of Najd Training Institutes, which was established in 1986 AD. Thus, the Support Services Institutes have become one of the leading and specialized institutes in the field of training and education. and development.

Sudair Pharmaceutical

Sudair Pharmaceutical Company (SPC) is a leading Saudi-based pharmaceutical firm specializing in specialty care medications. Established in 2014, SPC aims to address unmet medical needs in Saudi Arabia and the MENA region, with a focus on cancer-fighting medications and other high-tech treatments for chronic and life-threatening diseases. Al Hammadi Holding Company owns 35% of SPC’s shares, bolstering its commitment to improve healthcare provision and secure the supply of advanced pharmaceuticals. SPC’s innovative business model, international partnerships, and dedication to integrity, quality, innovation, and community service make it an integral player in achieving KSA’s 2030 vision for better health outcomes.

Biopharma Industrial Park

The Biopharma Industrial Park is a progressive subsidiary of Al Hammadi Holding, operating at the forefront of biotechnology and life sciences innovation. As a pivotal contributor to Al Hammadi’s comprehensive health care services, the Biopharma Industrial Park is committed to driving advancements in medical research, development, and production. Its focus on cutting-edge technologies and scientific expertise enables the organization to make significant strides in improving patient care, as well as advancing the medical sector within the Kingdom of Saudi Arabia and beyond.

Construction & Maintenance

The Construction and Maintenance Company is a subsidiary of Al Hammadi Holding, specializing in providing high-quality hospital maintenance, engineering works, and other related services. As an integral part of the Al Hammadi group, this company plays a crucial role in ensuring the smooth and efficient functioning of health care facilities while maintaining a safe and comfortable environment for patients and medical staff, the company recently obtained certificates in quality, safety and environmental management.

Home Medical Care

Home Medical Care, a subsidiary of Al Hammadi Holding, provides comprehensive and personalized healthcare services to patients in the comfort of their own homes. This innovative approach to healthcare delivery aims to enhance patient satisfaction, reduce hospital readmissions, and improve overall patient outcomes. By offering a wide range of medical services in a familiar and comfortable environment, Home Medical Care strives to promote patient well-being and independence.

Telemedicine

Telemedicine Company, a subsidiary of Al Hammadi Holding, is at the forefront of revolutionizing healthcare delivery by leveraging advanced technology to provide remote medical services. This innovative approach to healthcare enables patients to access quality medical care from the comfort of their homes or workplaces, eliminating geographical barriers and reducing the burden on traditional healthcare facilities.

Unified Procurement

Unified Procurement, a subsidiary of Al Hammadi Holding, is a specialized company responsible for managing all medical and non-medical hospital purchases and supplies. As an integral part of Al Hammadi’s comprehensive health care services, Unified Procurement plays a vital role in ensuring that hospitals and clinics have access to the necessary equipment, supplies, and consumables needed to provide high-quality care to their patients.

Arabian Hospitality

Arabian Hospitality, a subsidiary of Al Hammadi Holding, is a prominent player in the domain of hospital support services, dedicated to maintaining the highest standards of hygiene, laundry, medical staff attire, and food services for patients. As an integral part of the Al Hammadi Holding group, Arabian Hospitality ensures a seamless and comfortable experience for both patients and medical staff, contributing to the overall excellence of the group’s health care offerings, the company recently obtained the certificates of Quality Management, Food Safety, Hazard Analysis and Critical Control Points.

Al Hammadi Hospital Al Narjis

Al Narjis Hospital – Expected launch in 2028 .Building on this, Al Hammadi is expecting to launch its fourth hospital in 2028. The facility will have a capacity of 200 rooms and 120 clinics and will house two centers of excellence focused on rehabilitation and plastic surgery. The facility will be located in Al Narjis neighborhood in the north of the Kingdom’s capital.

Al Hammadi Hospital Al Olaya

Al Olaya Hospital – Expected Launch in 2026 .Al Olaya Hospital was Al Hammadi’s first facility, originally launched back in 1985. At its peak, the facility was home to 200 inpatient rooms and 74 outpatient clinics. The facility was temporarily shut down in the final months of 2021 as management kicked off an extensive renovation plan aimed at constructing a new facility with a new infrastructure and a broader service offering. The revamped facility, which is planned to reopen in 2026, will have a capacity of 200 rooms and 120 clinics and will operate two centers of excellence focused on sports medicine and oncology. The facility is located in the Al Olaya neighborhood of Riyadh, which has historically been a business, commerce, and leisure hub in the city, rendering it a natural residential destination for expats and a large number of Saudi citizens.

Al Hammadi Hospital Al Suwaidi

Launched in 2015, Al Suwaidi Hospital is located in a strategic southwest neighborhood of KSA’s capital. Today, the facility houses 300 inpatient rooms, 80 outpatient clinics, and 13 operating rooms. The facility also has a cardiac catheterization room, two upper and lower endoscopy rooms, a kidney stone treatment room, and a lithotripsy room. The facility is equipped with the highest quality machinery and medical technology in the market, and services are provided by highly trained and experienced medical professionals. As of year-end 2022, 160 rooms were operational at the facility, with the remaining unutilized rooms offering easy-to-ramp-up capacity to match growing demand. The facility caters to both a significant pool of patients associated with the MOH and private insurance patients primarily from the medium and medium-upper class segment.

Al Hammadi Hospital Al Nuzha

Located in a northeast neighborhood of Riyadh and officially inaugurated in 2018, Al Nuzha Hospital was originally launched to cater predominately to medium and upper-medium class patients, leveraging its 300-room capacity, 100 outpatient clinics, and 13 operating rooms. In 2022, the facility continued its premiumization, converting double rooms into single rooms to cater to increasing demand from higher-income class A/VIP patients and enabling the Group to capitalize on the important growth opportunities offered by this expanding segment. Today, Al Nuzha Hospital offers a comprehensive range of medical services, all provided by the facility’s highly experienced medical staff